Back to Rhode Island

H8318 • 2026

AN ACT RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT (Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.)

AN ACT RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT (Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.)

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Knight, Cortvriend, Caldwell, Alzate, Stewart, Kazarian, Casimiro, Dawson, Fogarty, Speakman
Last action
2026-03-30
Official status
Committee recommended measure be held for further study
Effective date
Not listed

Plain English Breakdown

The plain English breakdown is still being put together. The official documents below are already here.

Bill History

  1. 2026-03-30 Committee

    Committee recommended measure be held for further study

  2. 2026-03-26 Rhode Island General Assembly

    Scheduled for hearing and/or consideration (03/30/2026)

  3. 2026-03-18 Rhode Island General Assembly

    Introduced, referred to House Health & Human Services

Official Summary Text

AN ACT RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT (Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.)

Current Bill Text

Read the full stored bill text
H8318

2026 -- H 8318
========
LC006071
========

STATE OF RHODE ISLAND
IN GENERAL ASSEMBLY
JANUARY SESSION, A.D. 2026
____________
A N A C T
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT

Introduced By:
Representatives Knight, Cortvriend, Caldwell, Alzate, Stewart, Kazarian,
Casimiro, Dawson, Fogarty, and Speakman

Date Introduced:
March 18, 2026

Referred To:
House Health & Human Services
It is enacted by the General Assembly as follows:
1
SECTION 1. Section 21-28-3.18 of the General Laws in Chapter 21-28 entitled "Uniform
2
Controlled Substances Act" is hereby amended to read as follows:
3

21-28-3.18. Prescriptions.
4
(a) An apothecary in good faith may sell and dispense controlled substances in schedules
5
II, III, IV, and V to any person upon a valid prescription by a practitioner licensed by law to
6
prescribe or administer those substances; dated and signed by the person prescribing on the day
7
when issued and bearing the full name and address of the patient to whom, or of the owner of the
8
animal for which, the substance is dispensed; and the full name, address, and registration number
9
under the federal law of the person prescribing, if he or she is required by that law to be registered.
10
If the prescription is for an animal, it shall state the species of the animal for which the substance
11
is prescribed.
12
(b) When filling a hard-copy prescription for a schedule II controlled substance, the
13
apothecary filling the prescription shall sign his or her full name and shall write the date of filling
14
on the face of the prescription.
15
(c) The prescription shall be retained on file by the proprietor of the pharmacy in which it
16
was filled for a period of two (2) years so as to be readily accessible for inspection by any public
17
officer or employee engaged in the enforcement of this chapter.
18
(d)(1) Hard-copy prescriptions for controlled substances in schedule II shall be filed
19
separately and shall not be refilled.

1
(2) The director of health shall, after appropriate notice and hearing pursuant to § 42-35-3,
2
promulgate rules and regulations for the purpose of adopting a system for electronic data
3
transmission of prescriptions for controlled substances in schedules II, III, IV, and V. Opioid
4
antagonists, including, but not limited to, naloxone, as may be further determined by rules and
5
regulations, shall be transmitted with controlled substances in schedules II, III, IV, and V. Provided,
6
information collected regarding dispensing of opioid antagonists shall be for statistical, research,
7
or educational purposes only. The department’s rules and regulations shall require the removal of
8
patient, recipient, or prescriber information that could be used to identify individual patients or
9
recipients of opioid antagonists.
10

(i) Notwithstanding any other provision of this chapter or any regulation promulgated
11
thereunder, prescriptions for testosterone shall not be transmitted to, or reported within, the
12
prescription drug monitoring database maintained by the department of health.
13

(ii) Immediately upon the effective date of this subsection, the department of health and
14
human services shall purge from the records of the controlled substances prescriptions monitoring
15
program, as established in § 21-28-3.32, all existing information concerning the prescribing and
16
dispensing of testosterone and shall ensure that no further records concerning the prescribing or
17
dispensing of testosterone are created or maintained by the electronic prescription drug monitoring
18
program.
19
(3) A practitioner shall sign and transmit electronic prescriptions for controlled substances
20
in schedules II, III, IV, and V to a pharmacy in accordance with rules and regulations as shall be
21
promulgated by the department and which shall require electronic transmission no sooner than
22
January 1, 2020, and a pharmacy may dispense an electronically transmitted prescription for these
23
controlled substances in accordance with the code of federal regulations, 21 C.F.R., pt. 1300, et
24
seq.
25
(e) Subject to the rules and regulations promulgated by the department pursuant to
26
subsection (d)(3) of this section, a prescription for a schedule II narcotic substance to be
27
compounded for the direct administration to a patient by parenteral, intravenous, intramuscular,
28
subcutaneous, or intraspinal infusion may be transmitted by the practitioner, or practitioner’s agent,
29
to the pharmacy by facsimile. The facsimile will serve as the original prescription.
30
(f) Subject to the rules and regulations promulgated by the department pursuant to
31
subsection (d)(3) of this section, a prescription for a schedule II substance for a resident of a long-
32
term-care facility may be transmitted by the practitioner, or the practitioner’s agent, to the
33
dispensing pharmacy by facsimile. The facsimile serves as the original prescription.
34
(g) Subject to the rules and regulations promulgated by the department pursuant to

LC006071 - Page 2 of 8
1
subsection (d)(3) of this section, a prescription for a schedule II narcotic substance for a patient
2
residing in a hospice certified by Medicare under title XVIII of the Social Security Act, 42 U.S.C.
3
§ 1395 et seq., or licensed by the state, may be transmitted by the practitioner, or practitioner’s
4
agent, to the dispensing pharmacy by facsimile. The practitioner, or the practitioner’s agent, will
5
note on the prescription that the patient is a hospice patient. The facsimile serves as the original,
6
written prescription.
7
(h) An apothecary, in lieu of a written prescription, may sell and dispense controlled
8
substances in schedules III, IV, and V to any person upon an oral prescription of a practitioner. In
9
issuing an oral prescription, the prescriber shall furnish the apothecary with the same information
10
as is required by subsection (a) of this section and the apothecary who fills the prescription shall
11
immediately reduce the oral prescription to writing and shall inscribe the information on the written
12
record of the prescription made. This record shall be filed and preserved by the proprietor of the
13
pharmacy in which it is filled in accordance with the provisions of subsection (c) of this section. In
14
no case may a prescription for a controlled substance listed in schedules III, IV, or V be filled or
15
refilled more than six (6) months after the date on which the prescription was issued and no
16
prescription shall be authorized to be refilled more than five (5) times. Each refilling shall be
17
entered on the face or back of the prescription and note the date and amount of controlled substance
18
dispensed and the initials or identity of the dispensing apothecary.
19
(i) In the case of an emergency situation as defined in federal law, an apothecary may
20
dispense a controlled substance listed in schedule II upon receiving an oral authorization of a
21
prescribing practitioner provided that:
22
(1) The quantity prescribed and dispensed is limited to the amount adequate to treat the
23
patient during the emergency period and dispensing beyond the emergency period must be pursuant
24
to a written prescription signed by the prescribing practitioner.
25
(2) The prescription shall be immediately reduced to writing and shall contain all the
26
information required in subsection (a).
27
(3) The prescription must be dispensed in good faith in the normal course of professional
28
practice.
29
(4) Within seven (7) days after authorizing an emergency oral prescription, the prescribing
30
practitioner shall cause a prescription for the emergency quantity prescribed to be delivered to the
31
dispensing apothecary. The prescription shall have written on its face “authorization for emergency
32
dispensing” and the date of the oral order. The prescription, upon receipt by the apothecary, shall
33
be attached to the oral emergency prescription that had earlier been reduced to writing.
34
(j)(1) The partial filling of a prescription for a controlled substance listed in schedule II is

LC006071 - Page 3 of 8
1
permissible, if the apothecary is unable to supply the full quantity called for in a prescription or
2
emergency oral prescription and he or she makes a notation of the quantity supplied on the face of
3
the prescription or oral emergency prescription that has been reduced to writing. The remaining
4
portion of the prescription may be filled within seventy-two (72) hours of the first partial filling,
5
however, if the remaining portion is not, or cannot be, filled within seventy-two (72) hours, the
6
apothecary shall notify the prescribing practitioner. No further quantity may be supplied beyond
7
seventy-two (72) hours without a new prescription.
8
(2)(i) A prescription for a schedule II controlled substance written for a patient in a long-
9
term-care facility (LTCF), or for a patient with a medical diagnosis documenting a terminal illness,
10
may be filled in partial quantities to include individual dosage units. If there is a question whether
11
a patient may be classified as having a terminal illness, the pharmacist must contact the practitioner
12
prior to partially filling the prescription. Both the pharmacist and the prescribing practitioner have
13
a corresponding responsibility to assure that the controlled substance is for a terminally ill patient.
14
(ii) The pharmacist must record on the prescription whether the patient is “terminally ill”
15
or an “LTCF patient.” A prescription that is partially filled, and does not contain the notation
16
“terminally ill” or “LTCF patient,” shall be deemed to have been filled in violation of this chapter.
17
(iii) For each partial filling, the dispensing pharmacist shall record on the back of the
18
prescription (or on another appropriate record, uniformly maintained, and readily retrievable), the:
19
(A) Date of the partial filling;
20
(B) Quantity dispensed;
21
(C) Remaining quantity authorized to be dispensed; and
22
(D) Identification of the dispensing pharmacist.
23
(iv) The total quantity of schedule II controlled substances dispensed in all partial fillings
24
must not exceed the total quantity prescribed.
25
(v) Schedule II prescriptions for patients in a LTCF, or patients with a medical diagnosis
26
documenting a terminal illness, are valid for a period not to exceed sixty (60) days from the issue
27
date, unless sooner terminated by the discontinuance of medication.
28
(k)
Automated data-processing systems.
As an alternative to the prescription record-
29
keeping provision of subsection (h) of this section, an automated data-processing system may be
30
employed for the record-keeping system if the following conditions have been met:
31
(1) The system shall have the capability of producing sight-readable documents of all
32
original and refilled prescription information. The term “sight readable” means that an authorized
33
agent shall be able to examine the record and read the information. During the course of an on-site
34
inspection, the record may be read from the CRT, microfiche, microfilm, printout, or other method

LC006071 - Page 4 of 8
1
acceptable to the director. In the case of administrative proceedings, records must be provided in a
2
paper printout form.
3
(2) The information shall include, but not be limited to, the prescription requirements and
4
records of dispensing as indicated in subsection (h) of this section.
5
(3) The individual pharmacist responsible for completeness and accuracy of the entries to
6
the system must provide documentation of the fact that prescription information entered into the
7
computer is correct. In documenting this information, the pharmacy shall have the option to either:
8
(i) Maintain a bound logbook, or separate file, in which each individual pharmacist
9
involved in the dispensing shall sign a statement each day attesting to the fact that the prescription
10
information entered into the computer that day has been reviewed and is correct as shown. The
11
book or file must be maintained at the pharmacy employing that system for a period of at least two
12
(2) years after the date of last dispensing; or
13
(ii) Provide a printout of each day’s prescription information. That printout shall be
14
verified, dated, and signed by the individual pharmacist verifying that the information indicated is
15
correct. The printout must be maintained at least two (2) years from the date of last dispensing.
16
(4) An auxiliary, record-keeping system shall be established for the documentation of
17
refills if the automated data-processing system is inoperative for any reason. The auxiliary system
18
shall ensure that all refills are authorized by the original prescription and that the maximum number
19
of refills is not exceeded. When this automated data-processing system is restored to operation, the
20
information regarding prescriptions filled and refilled during the inoperative period shall be entered
21
into the automated data-processing system within ninety-six (96) hours.
22
(5) Any pharmacy using an automated data-processing system must comply with all
23
applicable state and federal laws and regulations.
24
(6) A pharmacy shall make arrangements with the supplier of data-processing services or
25
materials to ensure that the pharmacy continues to have adequate and complete prescription and
26
dispensing records if the relationship with the supplier terminates for any reason. A pharmacy shall
27
ensure continuity in the maintenance of records.
28
(7) The automated data-processing system shall contain adequate safeguards for security
29
of the records to maintain the confidentiality and accuracy of the prescription information.
30
Safeguards against unauthorized changes in data after the information has been entered and verified
31
by the registered pharmacist shall be provided by the system.
32
(l) Prescriptions for controlled substances as found in schedule II will become void unless
33
dispensed within ninety (90) days of the original date of the prescription and in no event shall more
34
than a thirty-day (30) supply be dispensed at any one time, with the exception of prescriptions for

LC006071 - Page 5 of 8
1
non-opioid, non-narcotic controlled substances found in schedule II, where a ninety-day (90)
2
supply but in no event more than a ninety-day (90) supply, may be dispensed at any one time.
3
(1) In prescribing controlled substances in schedule II, practitioners may write up to three
4
(3) separate prescriptions, each for up to a one-month supply, each signed and dated on the date
5
written. For those prescriptions for the second and/or third month, the practitioner must write the
6
earliest date each of those subsequent prescriptions may be filled, with directions to the pharmacist
7
to fill no earlier than the date specified on the face of the prescription.
8
(m) The prescriptions in schedules III, IV, and V will become void unless dispensed within
9
one hundred eighty (180) days of the original date of the prescription. For purposes of this section,
10
a “dosage unit” shall be defined as a single capsule, tablet, or suppository, or not more than one
11
five (5) ml. of an oral liquid.
12
(1) Prescriptions in schedule III cannot be written for more than one hundred (100) dosage
13
units and not more than one hundred (100) dosage units may be dispensed at one time. Provided,
14
however, manufacturer prepackaged steroids and hormones in schedule III shall be exempt from
15
this subsection.
16
(2) Prescriptions in schedules IV and V may be written for up to a ninety-day (90) supply
17
based on directions. No more than three hundred and sixty (360) dosage units may be dispensed at
18
one time.
19
(n) A pharmacy shall transmit prescription information to the prescription-monitoring
20
database at the department of health within one business day following the dispensing of an opioid
21
prescription.
22
(o) The pharmacist shall inform patients verbally or in writing about the proper disposal of
23
expired, unused, or unwanted medications, including the location of local disposal sites as listed on
24
the department of health website.
25
(p) The pharmacist shall inform patients verbally or in writing in the proper use of any
26
devices necessary for the administration of controlled substances.
27
(q)(1) A healthcare professional authorized to issue prescriptions shall, prior to issuing an
28
initial prescription for an opioid drug, specifically discuss with the patient who is eighteen (18)
29
years of age or older, or the patient’s parent or guardian if the patient is under eighteen (18) years
30
of age, the risks of developing a dependence or addiction to the prescription opioid drug and
31
potential of overdose or death; the adverse risks of concurrent use of alcohol or other psychoactive
32
medications and the patient’s or the minor patient’s parent or guardian’s responsibility to safeguard
33
all medications; and, if the prescriber deems it appropriate, discuss such alternative treatments as
34
may be available. For patients in recovery from substance dependence, education shall be focused

LC006071 - Page 6 of 8
1
on relapse risk factors. This discussion shall be noted in the patient’s record.
2
(2) The director of the department of health shall develop and make available to prescribers
3
guidelines for the discussion required pursuant to this subsection.
4
(3) The discussion required under this subsection shall not be required prior to issuing a
5
prescription to any patient who is currently receiving hospice care from a licensed hospice.
6
(r) Effective January 1, 2025, in recognition of the United States Drug Enforcement
7
Agency (DEA) revised regulations regarding electronic prescription refills permitting DEA
8
registered pharmacies to transfer electronic prescriptions at a patient’s request, the department of
9
health shall amend its regulations to reflect this change following the Centers for Medicare and
10
Medicaid’s designation for the standard the pharmacy industry must use to support Medicare
11
electronic prescribing and related transactions to permit the transfer of electronic prescriptions.
12
SECTION 2. This act shall take effect upon passage.
========
LC006071
========

LC006071 - Page 7 of 8
EXPLANATION
BY THE LEGISLATIVE COUNCIL
OF
A N A C T
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
***
1
This act would not allow prescriptions for testosterone to be transmitted or reported within
2
the prescription drug monitoring database and would remove from the records all existing
3
information concerning prior testosterone prescriptions.
4
This act would take effect upon passage.
========
LC006071
========

LC006071 - Page 8 of 8